Pfizer CentreOne to manufacture Sobi’s Kineret® drug substance

Monday, June 6, 2016
Announcement

Agreement covers current and future indications

Pfizer CentreOne recently signed an agreement with Swedish Orphan Biovitrum AB (publ) (Sobi™) to manufacture the drug substance for Sobi’s Kineret®, a drug used to treat certain types of severe autoinflammatory conditions. Pfizer CentreOne is a global contract manufacturer that focuses on API synthesis and sterile injectables fill-finish. Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare-disease patients and their families.

“We are pleased to work with Sobi to provide long-term supply for this important medication,” said Peter Stevenson, Vice President and General Manager of Pfizer CentreOne. Technology transfer is underway to one of Pfizer's manufacturing sites, in Strängnäs, Sweden, which will produce the drug substance.

Said Kirsti Gjellan, Senior Vice President Biologics Development and Supply at Sobi, “Our partnership with Pfizer CentreOne will enable Sobi to provide a reliable and sustainable supply of Kineret to patients in a cost-effective way and will also significantly expand capacity to support Sobi’s work to grow Kineret in existing and planned indications.”